This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

69/100

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Results A total of 1169 individuals were included from A4 Study and 538 without elevated amyloid PET were included from the LEARN Study. Levels of plasma p-tau217 increased significantly in Aβ+ participants before showing significant deceleration (χ2 = 21.7; P Conclusions and relevance This study found that tau PET is valuable for both prognostic and real-time tracking of disease progression.

Key findings

Results A total of 1169 individuals were included from A4 Study and 538 without elevated amyloid PET were included from the LEARN Study.
Levels of plasma p-tau217 increased significantly in Aβ+ participants before showing significant deceleration (χ2 = 21.7; P Conclusions and relevance This study found that tau PET is valuable for both prognostic and real-time tracking of disease progression.

Why it matters

In participants from the A4 and LEARN studies, plasma p-tau217 increased significantly in amyloid-positive individuals before slowing down. The authors concluded that tau PET is valuable for both predicting and tracking disease progression in preclinical Alzheimer's disease.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcohort
Participants1,707
Effect sizeBaseline plasma p-tau217 correlation with cognitive change ρ = -0.47; concurrent change ρ = -0.24
Evidence strengthModerate

How this study scored 69/100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomised / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 68 of the 98 points we could judge it on, which is 69 out of 100.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA Neurology)
Journal's citation record	2 / 4	JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	3 / 4	1,707 participants
Effect reported	3 / 3	Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 29 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	9.7 citations a year over 3 year(s) since 2025
Impact for its field and year	4 / 6	Cited 18.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 3 other studies in this library
Still being cited	2 / 4	Cited 29 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Michael Donohue: h-index 87 (OpenAlex, whole career)
Institution's track record	3 / 3	Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 9 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40853684)
Free to read	— / 2	Access not recorded — left out of this score
Points	68 / 98	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 68 of the 98 points we could judge it on is 69 out of 100.
Total	69 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 11 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Insel, P. S., Mattsson-Carlgren, N., Langford, O., Caruso, V. M., Leuzy, A., Young, C. B., et al. (2025). Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2025.2974

Vancouver

Insel PS, Mattsson-Carlgren N, Langford O, Caruso VM, Leuzy A, Young CB, et al. Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease. JAMA Neurology. 2025. doi:10.1001/jamaneurol.2025.2974. PMID: 40853684.

BibTeX

@article{insel2025-40853684,
  author  = {Insel, P. S. and Mattsson-Carlgren, N. and Langford, O. and Caruso, V. M. and Leuzy, A. and Young, C. B. and Boxer, A. and Aisen, P. S. and Sperling, R. A. and Mormino, E. C. and Donohue, M. C.},
  title   = {{Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease}},
  journal = {JAMA Neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.2974},
  pmid    = {40853684},
  url     = {https://doi.org/10.1001/jamaneurol.2025.2974}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Biomarkers

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Biomarkers

See all studies in Biomarkers →